A5061986575- Lipoproteins and Cardiovascular Health
- Health Systems, Economic Evaluations, Quality of Life
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pharmaceutical Economics and Policy
- Lipid metabolism and disorders
- Prostate Cancer Treatment and Research
- Cholesterol and Lipid Metabolism
- Prostate Cancer Diagnosis and Treatment
- Adipose Tissue and Metabolism
- Musculoskeletal pain and rehabilitation
- Antiplatelet Therapy and Cardiovascular Diseases
- Liver Disease Diagnosis and Treatment
- Glaucoma and retinal disorders
- Biosimilars and Bioanalytical Methods
- Adipokines, Inflammation, and Metabolic Diseases
- Atherosclerosis and Cardiovascular Diseases
- Healthcare Policy and Management
- Aquaculture Nutrition and Growth
- Metabolism, Diabetes, and Cancer
- Liver Disease and Transplantation
- Ubiquitin and proteasome pathways
- Neurobiology of Language and Bilingualism
- Diabetes Treatment and Management
- Uterine Myomas and Treatments
Myovant Sciences (United States)
2022-2024
Western University
2021
Robarts Clinical Trials
2021
Vector Oncology (United States)
2018-2019
West Cancer Center
2019
Eli Lilly (United States)
2019
Merck & Co., Inc., Rahway, NJ, USA (United States)
2019
Genomics (United Kingdom)
2019
Institute for Transfusion Medicine
2019
Actelion (United States)
2019
In a previous study, single injection of inclisiran, chemically synthesized small interfering RNA designed to target PCSK9 messenger RNA, was found produce sustained reductions in low-density lipoprotein (LDL) cholesterol levels over the course 84 days healthy volunteers.We conducted phase 2, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial inclisiran administered as subcutaneous patients at high risk for cardiovascular disease who had elevated LDL levels....
To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). In two randomized, double-blind studies (ODYSSEY FH I, n = 486; II, 249), were randomized 2 : 1 to 75 mg or placebo every weeks (Q2W). Alirocumab dose was increased at Week 12 150 Q2W if 8 ≥1.8 mmol/L (70 mg/dL). Primary endpoint (both studies) percentage change calculated from baseline 24....
Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Despite statins and additional lipid-lowering therapies, many HeFH patients fail achieve low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, further lower LDL-C in with disease.This double-blind, placebo-controlled, phase 3 trial randomized disease on maximally tolerated statin ≥2.6 mmol/L (≥100 mg/dL)...
A goal of second language (L2) learning is to enable learners understand and speak L2 words without mediation through the first (L1). However, psycholinguistic research suggests that lexical candidates are routinely activated in L1 when processed. In this article we describe two experiments examined acquisition fluency. Experiment 1, groups native English speakers, one more less fluent French as their L2, performed word naming translation tasks. Learners were slower error prone name...
During early stages of second language acquisition adult learners make frequent errors lexical form. An experiment was performed to examine this effect in the laboratory. More and less fluent bilinguals English Spanish a translation recognition task which they decided whether two words correct first. In critical conditions were not equivalents, but related by form (e.g., man-hambre (hunger) instead man-hombre (man)) or meaning man-mujer (woman) (man)). Less participants suffered more...
No AccessJournal of UrologyAdult Urology1 Mar 2013Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template in the Detection Clinically Significant Cancer Veeru Kasivisvanathan, Robert Dufour, Caroline M. Moore, Hashim U. Ahmed, Mohamed Abd-Alazeez, Susan C. Charman, Alex Freeman, Clare Allen, Kirkham, Jan van der Meulen, and Mark Emberton KasivisvanathanVeeru Kasivisvanathan Division Surgery Interventional Sciences, University College London, United...
A protein that is expressed on capillary endothelial cells, called GPIHBP1 (glycosylphosphatidylinositol-anchored high-density lipoprotein binding 1), binds lipase and shuttles it to its site of action in the lumen. deficiency prevents from reaching Patients with have low plasma levels lipase, impaired intravascular hydrolysis triglycerides, severe hypertriglyceridemia (chylomicronemia). During characterization a monoclonal antibody-based immunoassay for GPIHBP1, we encountered two samples...
We assessed whether patients with familial isolated vitamin E deficiency could discriminate between natural (RRR-) and synthetic (SRR-) stereoisomers of alpha-tocopherol labeled six (d6) or three (d3) deuterium atoms, respectively. After oral administration 20 mg each the stereoisomers, (seven) controls had similar concentrations both in chylomicrons, initial increases both, rates decrease d3-SRR-alpha-tocopherol plasma. Patients differed their abilities to maintain plasma...
AbstractFamilial hypercholesterolemia (FH) is an autosomal codominant lipoprotein disorder characterized by elevated low-density cholesterol (LDL-C) and high risk of premature atherosclerotic cardiovascular disease. Definitions for FH rely on complex algorithms that are the basis levels total or LDL-C, clinical features, family history, DNA analysis often difficult to obtain. We propose a novel simplified definition FH. Definite includes: (1) LDL-C (≥ 8.50 mmol/L); (2) ≥ 5.0 mmol/L (for age...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a downregulator of the low density lipoprotein receptor. The aims this cross-sectional cohort-study were to examine whether PCSK9 R46L loss function variant found in cohort familial hypercholesterolemia (FH) patients was associated with lower cholesterol, frequency xanthomata, and cardiovascular risk.We studied FH attending IRCM (Institut de Recherches Cliniques Montréal) Lipid Clinic whose DNA genotyping positive for receptor...
Abstract BACKGROUND Familial hypercholesterolemia (FH) is the most frequent genetic disorder seen clinically and characterized by increased LDL cholesterol (LDL-C) (>95th percentile), family history of LDL-C, premature atherosclerotic cardiovascular disease (ASCVD) in patient or first-degree relatives, presence tendinous xanthomas corneal arcus, a pathogenic mutation LDLR, PCSK9, APOB genes. A diagnosis FH has important clinical implications with respect to lifelong risk ASCVD...
Background and aimsODYSSEY OLE (open-label extension; NCT01954394) included patients diagnosed with heterozygous familial hypercholesterolemia (HeFH), receiving maximally tolerated statins, who had completed one of four Phase 3 double-blind parent studies (all 18 months' duration), the aim to assess longer-term safety efficacy alirocumab.MethodsPatients received starting dose alirocumab 75 mg every 2 weeks (Q2W; from FH I, II, LONG TERM) or 150 Q2W (patients HIGH FH). Low-density lipoprotein...